Invictus' Acreage Pharms Receives Notification of Sales license Inspection
March 06 2018 - 6:00AM
InvestorsHub NewsWire
Invictus’ Acreage
Pharms Receives Notification of Sales license
Inspection
Vancouver, BC -- March 06, 2018 -- InvestorsHub
NewsWire -- INVICTUS MD STRATEGIES CORP.’s ("Invictus" or the
"Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS1)
Acreage Pharms Ltd. (“Acreage Pharms”) is pleased
to announce that it has received notification from Health Canada
(HC) that its sales license inspection has been
scheduled for later in March and is anticipated to take up to three
days. The Sales License Inspection is the last step prior to the
issuance of a Sales License under the Access to Cannabis for
Medical Purposes Regulations (the "ACMPR")
"As there are currently only 40
cannabis sales licenses under the ACMPR in Canada, receiving
confirmation of our Sales License Inspection from Health Canada is
a major milestone for Acreage Pharms. I'm extremely proud of our
CEO at Acreage Pharms, Trevor Dixon and our cultivation team. Their
dedication shows in the high-quality flower being produced at
Acreage Pharms. Our team's ability to execute has allowed us to
advance to the Pre-Sales License Inspection for which I am
delighted,” said Dan Kriznic, Chairman and CEO of
Invictus.
Currently Acreage Pharms has a total
of 191 kilograms of dried marijuana in their vault. Invictus’ AB
Laboratories Inc. (“AB Labs”) received its
amendment to sell dried marijuana under the ACMPR in January
2018.
About Invictus MD Strategies Corp.
Invictus MD Strategies Corp. is focused on two main verticals
within the Canadian cannabis sector, namely the Licensed
Producers under the ACMPR, being its 100% investment in Acreage
Pharms Ltd., located in West-Central Alberta, and 50% investment in
AB Laboratories Inc., located near Hamilton, Ontario which has both
its cultivation and sales license under ACMPR. In addition to ACMPR
licenses, the Company has an 82.5% investment in Future Harvest
Development Ltd. a Fertilizer and Nutrients manufacturer based
in Kelowna, British Columbia.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
Dan Kriznic
Chairman & CEO
Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676
Cautionary Note Regarding Forward-Looking Statements: This release
includes certain statements and information that may constitute
forward-looking information within the meaning of applicable
Canadian securities laws or forward-looking statements within the
meaning of the United States Private Securities Litigation Reform
Act of 1995. All statements in this news release, other than
statements of historical facts, including statements regarding
future estimates, plans, objectives, timing, assumptions or
expectations of future performance, including the potential
production capacity of AB Labs, AB Ventures and Acreage Pharms’
production facilities, the granting of regulatory approval and
anticipated timing of AB Labs reaching full production capacity,
the granting of a sales license under the ACMPR to AB Ventures and
Acreage Pharms, Acreage Pharms’ receipt of a sales license and the
success and timing of Acreage Pharms’ expansion plans, expected
sales of inventory and the completion of the increase in the
Company’s ownership of AB Labs pursuant to the definitive agreement
(the “Transaction”) are forward-looking statements and contain
forward-looking information. Generally, forward-looking statements
and information can be identified by the use of forward-looking
terminology such as “intends” or “anticipates”, or variations of
such words and phrases or statements that certain actions, events
or results “may”, “could”, “should”, “would” or “occur”.
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including the assumptions that AB Labs, AB Ventures and Acreage
Pharms will satisfy all conditions for, and receive, regulatory
approval to sell medical cannabis at their production facilities’
full capacity, AB Ventures will satisfy all conditions for and be
granted a license under the ACMPR and will receive a development
permit on the expected terms, AB Ventures is able to successfully
build a production facility, Acreage Pharms will satisfy all
conditions for and successfully obtain the anticipated sales
license and will successfully complete its expansion plans, the
anticipated sales of inventory will take place on the terms and
timing expected by management, all conditions to the closing of the
Transaction will be satisfied and the Transaction will complete on
the terms set out in the definitive agreement and that the
legalization of recreational use of cannabis in Canada will occur
as expected. These forward-looking statements are subject to known
and unknown risks, uncertainties and other factors that may cause
the actual results, level of activity, performance or achievements
of the Company to be materially different from those expressed or
implied by such forward-looking statements or forward-looking
information. Important factors that may cause actual results to
vary, include, without limitation, the risk that AB Labs, AB
Ventures and Acreage Pharms will not receive regulatory approval to
sell medical cannabis at their production facilities for their full
production capacity or at all, that AB Labs, AB Ventures or Acreage
Pharms will not reach full production capacity, that AB Ventures
will not be granted a license under the ACMPR or will not receive a
development permit on the expected terms or at all, that AB
Ventures is not able to successfully build a production facility,
that Acreage Pharms is not able to obtain the anticipated sales
license when expected by management or at all or is not able to
successfully complete its expansion plans, that the anticipated
sales of inventory will not occur on the terms and timing expected
by management or at all, that the Transaction will not complete on
the expected terms or at all and that the legalization of
recreational use of cannabis in Canada will not occur at all or as
expected. Although management of the Company has attempted to
identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward-looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
out-look that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbor.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Invictus MD Strategies (CE) (USOTC:IVITF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Invictus MD Strategies (CE) (USOTC:IVITF)
Historical Stock Chart
From Sep 2023 to Sep 2024